Investor Overview

Investors

Additional Resources

Shareholder Tools

Print Page
Email Page
Email Alerts
RSS Feeds
Financial Tear Sheet

NASDAQ: XBIT0.134.95Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News

Date	Title
06/09/17	XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
06/01/17	XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
05/30/17	Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer

Upcoming Events

There are currently no events scheduled.